Leo Pharma failed on the top line yet succeeded on profit in 2020
Leo Pharma's 2020 revenue did not quite reach DKK 11bn, but CEO Catherine Mazzacco notes that the firm has managed well in a Covid-19-impacted market. Now she looks forward to an eventful launch year.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Like for many other companies, the coronavirus pandemic has had a heavy impact on Leo Pharma, and this is the primary factor in the company's having missed its 2020 revenue guidance.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
